FDA approves Lilly drug for common advanced breast cancer
U.S. regulators have approved a new medicine for treating a common type of breast cancer after it has spread to other parts of the body.
Cancer
Articles
IU, Purdue get $2.55M to study breast cancer
Researchers at Indiana University and Purdue University have received $2.55 million from Susan G. Komen to study possible new treatments.
Lilly breast cancer drug results could challenge Pfizer pill
li Lilly and Co.’s experimental breast cancer drug abemaciclib, when combined with standard therapy, slowed the progression of tumors in patients with an advanced form of the disease.
Community makes latest push into oncology with $60M cancer center
Community Health Network’s new Cancer Center North, which will have its grand opening Saturday is designed to lift patients’ spirits as much as kill cancer cells.
Cancer often comes down to random chance, study says
Lifestyle and heredity get the most blame for cancer, but new research suggests random chance plays a bigger role than people realize.
Chinese firm working with Lilly gets positive results on cancer drug
Hutchison China MediTech Ltd., the biotechnology company that has a partnership with Eli Lilly and Co., on Friday reported positive late-stage results for its drug to treat colorectal cancer.
Purdue-based firm could change radiation treatments
Purdue University Professor You-Yeon Won’s development, called radio-luminescent nanoparticles, is designed to enhance the cancer-cell-killing effects of radiation treatment.
Lilly shares rise after Alimta cancer drug patent upheld on appeal
Teva Pharmaceuticals Industries Ltd.’s proposed generic version infringes a patent on the multi-billion-dollar patent, the U.S. Court of Appeals for the Federal Circuit ruled.
My body is the battleground between cancer and chemo
The point of chemo is to cure me. But these are not gentle chemicals. They sweep through my body like a tornado, with side effects that range from annoying to horrendous. But I have no choice.
Lilly cancer drug lands accelerated FDA approval
Lartruvo is the first front-line therapy approved by the FDA to treat soft tissue sarcomas since doxorubicin more than 40 years ago.
Purdue startup focuses on prostate cancer therapy
Research developed at Purdue University and licensed by a biomedical startup could give patients with late-stage prostate cancer an alternative to hormone therapies that can develop resistance after prolonged use.
Biotech firm lands funding for cancer targeting
Animated Dynamics Inc. has raised $1.7 million in early funding to help it get its technology to market.
Bristol-Myers drug tops Lilly’s Erbitux in cancer study
Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo prolonged survival in cases of recurrent head and neck cancer, a first for patients with the harshest form of the disease who often face a bleak prognosis.
Governor weighs in on criticism of HPV vaccine letter
The Indiana State Department of Health sent letters to 305,000 parents who haven’t vaccinated their children for a virus known to cause cervical cancer. Conservative groups have objected to what they call an intrusion into parenting decisions.
Lilly leaps into new frontier of cancer drugs
For two years, Eli Lilly and Co. has been building a team of immuno-oncology researchers in New York City and has struck a series of deals with other drug companies.
Lilly partner Immunocore raises record $320 million
Immunocore Ltd., which this week achieved the biggest private fundraising by a European biotechnology firm in 10 years, plans to accelerate development of its cancer therapy using the money and seek expedited approval.
Clot risk in Lilly lung-cancer drug raises FDA concerns
The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, Food and Drug Administration staff said in a report Tuesday.
Lilly drug regimen costing $9,200 a month scores zero in study
In a new scoring system for oncology drugs, a leading group of U.S. cancer doctors awarded a zero for overall benefit to a regimen featuring Alimta, Eli Lilly and Co.’s top-selling product.
7-year-old Simon Cancer Center already outmoded
The Indiana University Simon Cancer Center appears ill-suited for the future of cancer care and its own future is in question.
Lilly pledges $60M to German firm to form research partnership
In a bid to get into the white-hot market for drugs that use the body’s immune system, Eli Lilly and Co. will spend $60 million to form a research partnership with Germany-based BioNTech.